title: Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis: Is Intrathecal Anti-CD20 a Therapeutic Option?
authors.affiliation: Institute of Neuropathology, University Medical Centre, Göttingen, Germany2Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Science, Isfahan, Iran.
authors.forename: Mahboobeh
authors.initials: M
authors.lastname: Fereidan-Esfahani
authors.affiliation: Institute of Neuropathology, University Medical Centre, Göttingen, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Brück
authors.affiliation: Institute of Neuropathology, University Medical Centre, Göttingen, Germany3Department of Neurology, University Medical Centre, Göttingen, Germany.
authors.forename: Martin S
authors.initials: MS
authors.lastname: Weber
mesh_terms: D000906:Antibodies / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000502:physiology*; D002490:Central Nervous System / Q000473:pathology*; D006801:Humans; D007278:Injections, Spinal; D009103:Multiple Sclerosis / Q000188:drug therapy*; D017464:Receptors, Complement 3d / Q000276:immunology*
chemical_list: D000906:Antibodies; D017464:Receptors, Complement 3d